home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

113.75 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

BioNTech to Host Innovation Series R&D Day on November 14, 2024

October 31, 2024

From BioNTech SE

Via GlobeNewswire

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? ↗

October 24, 2024

This drugmaker's lead candidate could become a top-selling cancer therapy.

Via The Motley Fool

FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment ↗

October 21, 2024

BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current participants continue treatment, and other trials remain unaffected.

Via Benzinga

BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024

October 21, 2024

From BioNTech SE

Via GlobeNewswire

Forecasting The Future: 15 Analyst Projections For BioNTech ↗

October 07, 2024

Via Benzinga

Forecasting The Future: 8 Analyst Projections For BioNTech ↗

September 13, 2024

Via Benzinga

Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology ↗

October 17, 2024

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.

Via Benzinga

Topics Lawsuit

GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement ↗

October 15, 2024

GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine...

Via Benzinga

Topics Intellectual Property Lawsuit

Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake ↗

October 07, 2024

Shares peaked near 62 in late 2021, but are now worth less than half of that.

Via Investor's Business Daily

4 Reasons Pfizer Could Be a Value Play You Can't Miss

October 07, 2024

Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71

Via MarketBeat

Market Whales and Their Recent Bets on BNTX Options ↗

September 13, 2024

Via Benzinga

Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 07, 2024

Via Benzinga

Consumer Tech News (Sept 30-Oct 4): Latest Windows 11 Update Causing Trouble, Apple Accused Of Compelling Employees To Sign Illegal Agreements & More ↗

October 06, 2024

Major tech companies lobby against CA bill regulating AI, Apple faces legal complaints, iPhone users retain devices longer. Google warns Apple app removal.

Via Benzinga

Topics Artificial Intelligence Law Enforcement

Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research ↗

October 02, 2024

This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research.

Via Benzinga

Topics Artificial Intelligence

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

October 01, 2024

From BioNTech SE

Via GlobeNewswire

Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 24, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

September 20, 2024

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

September 20, 2024

From BioNTech SE

Via GlobeNewswire

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

September 17, 2024

From BioNTech SE

Via GlobeNewswire

Here's Why Everyone's Talking About Summit Therapeutics ↗

September 17, 2024

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

Via The Motley Fool

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions ↗

September 16, 2024

Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...

Via Benzinga

Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio? ↗

September 15, 2024

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.

Via Benzinga

Should You Buy Novavax Stock After This Regulatory Win? ↗

September 13, 2024

The biotech continues to earn important wins, but is it enough?

Via The Motley Fool

GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech ↗

September 11, 2024

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...

Via Benzinga

Why Is Moderna Stock Trading Higher On Monday? ↗

September 09, 2024

Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu...

Via Benzinga

Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows ↗

September 06, 2024

Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys.

Via Benzinga

BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

September 05, 2024

From BioNTech SE

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com